PURPOSE: hMena, member of the enabled/vasodilator-stimulated phosphoprotein family, is a cytoskeletal protein that is involved in the regulation of cell motility and adhesion. The aim of this study was to determine whether or not the expression of hMena isoforms correlated with sensitivity to EGFR tyrosine kinase inhibitors and could serve as markers with potential clinical use. EXPERIMENTAL DESIGN: Human pancreatic ductal adenocarcinoma cell lines were characterized for in vitro sensitivity to erlotinib, expression of HER family receptors, markers of epithelial to mesenchymal transition, and expression of hMena and its isoform hMena(+11a). The effects of epidermal growth factor (EGF) and erlotinib on hMena expression as well as the effect of hMena knockdown on cell proliferation were also evaluated. RESULTS: hMena was detected in all of the pancreatic tumor cell lines tested as well as in the majority of the human tumor samples [primary (92%) and metastatic (86%)]. Intriguingly, in vitro hMena(+11a) isoform was specifically associated with an epithelial phenotype, EGFR dependency, and sensitivity to erlotinib. In epithelial BxPC3 cells, epidermal growth factor up-regulated hMena/hMena(+11a) and erlotinib down-regulated expression. hMena knockdown reduced cell proliferation and mitogen-activated protein kinase and AKT activation in BxPC3 cells, and promoted the growth inhibitory effects of erlotinib. CONCLUSIONS: Collectively, our data indicate that the hMena(+11a) isoform is associated with an epithelial phenotype and identifies EGFR-dependent cell lines that are sensitive to the EGFR inhibitor erlotinib. The availability of anti-hMena(+11a)-specific probes may offer a new tool in pancreatic cancer management if these results can be verified prospectively in cancer patients.
PURPOSE:hMena, member of the enabled/vasodilator-stimulated phosphoprotein family, is a cytoskeletal protein that is involved in the regulation of cell motility and adhesion. The aim of this study was to determine whether or not the expression of hMena isoforms correlated with sensitivity to EGFR tyrosine kinase inhibitors and could serve as markers with potential clinical use. EXPERIMENTAL DESIGN:Humanpancreatic ductal adenocarcinoma cell lines were characterized for in vitro sensitivity to erlotinib, expression of HER family receptors, markers of epithelial to mesenchymal transition, and expression of hMena and its isoform hMena(+11a). The effects of epidermal growth factor (EGF) and erlotinib on hMena expression as well as the effect of hMena knockdown on cell proliferation were also evaluated. RESULTS:hMena was detected in all of the pancreatic tumor cell lines tested as well as in the majority of the humantumor samples [primary (92%) and metastatic (86%)]. Intriguingly, in vitro hMena(+11a) isoform was specifically associated with an epithelial phenotype, EGFR dependency, and sensitivity to erlotinib. In epithelial BxPC3 cells, epidermal growth factor up-regulated hMena/hMena(+11a) and erlotinib down-regulated expression. hMena knockdown reduced cell proliferation and mitogen-activated protein kinase and AKT activation in BxPC3 cells, and promoted the growth inhibitory effects of erlotinib. CONCLUSIONS: Collectively, our data indicate that the hMena(+11a) isoform is associated with an epithelial phenotype and identifies EGFR-dependent cell lines that are sensitive to the EGFR inhibitor erlotinib. The availability of anti-hMena(+11a)-specific probes may offer a new tool in pancreatic cancer management if these results can be verified prospectively in cancerpatients.
Authors: H Oettle; D Richards; R K Ramanathan; J L van Laethem; M Peeters; M Fuchs; A Zimmermann; W John; D Von Hoff; M Arning; H L Kindler Journal: Ann Oncol Date: 2005-08-08 Impact factor: 32.976
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley Journal: Proc Natl Acad Sci U S A Date: 2005-02-24 Impact factor: 11.205
Authors: M Wagner; T Cao; M E Lopez; C Hope; K van Nostrand; M S Kobrin; H U Fan; M W Büchler; M Korc Journal: Int J Cancer Date: 1996-12-11 Impact factor: 7.396
Authors: W Jeffrey Petty; Konstantin H Dragnev; Vincent A Memoli; Yan Ma; Neil B Desai; Adrian Biddle; Thomas H Davis; William C Nugent; Natalie Memoli; Marta Hamilton; Kenneth K Iwata; James R Rigas; Ethan Dmitrovsky Journal: Clin Cancer Res Date: 2004-11-15 Impact factor: 12.531
Authors: Stuart Thomson; Elizabeth Buck; Filippo Petti; Graeme Griffin; Eric Brown; Nishal Ramnarine; Kenneth K Iwata; Neil Gibson; John D Haley Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: J Rubin Grandis; M F Melhem; W E Gooding; R Day; V A Holst; M M Wagener; S D Drenning; D J Tweardy Journal: J Natl Cancer Inst Date: 1998-06-03 Impact factor: 13.506
Authors: Evanthia T Roussos; Michele Balsamo; Shannon K Alford; Jeffrey B Wyckoff; Bojana Gligorijevic; Yarong Wang; Maria Pozzuto; Robert Stobezki; Sumanta Goswami; Jeffrey E Segall; Douglas A Lauffenburger; Anne R Bresnick; Frank B Gertler; John S Condeelis Journal: J Cell Sci Date: 2011-07-01 Impact factor: 5.285
Authors: Evanthia T Roussos; Sumanta Goswami; Michele Balsamo; Yarong Wang; Robert Stobezki; Esther Adler; Brian D Robinson; Joan G Jones; Frank B Gertler; John S Condeelis; Maja H Oktay Journal: Clin Exp Metastasis Date: 2011-04-12 Impact factor: 5.150